Status:
COMPLETED
Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract
Lead Sponsor:
Catalysis SL
Conditions:
Renal Injury
Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Given the high recurrence of urolithiasis in patients, the search for less aggressive and preventive treatments is increasingly necessary. Renalof® is presented as an alternative to herbal medicine be...
Detailed Description
Given the high recurrence of urolithiasis in patients, the search for less aggressive and preventive treatments is increasingly necessary. Renalof® is presented as an alternative to herbal medicine be...
Eligibility Criteria
Inclusion
- Patient over 18 years of age, in all their mental and physical capacities to decide to be part of this study.
- There are no comorbidities or associated diseases that put the stability of the patient at risk.
- Not be diagnosed as Chronic Kidney Disease, in any stage.
- Existence of non-obstructive stones smaller than 10 mm located in the renoureteral path.
- No compromise of renal viability.
Exclusion
- Patients under 18 years of age.
- Existence of comorbidities or associated diseases that put the stability of the patient at risk.
- Existence of a diagnosis of Chronic Kidney Disease, at any stage.
- Presence of non-obstructive or obstructive stones greater than 10 mm located in the renoureteral path.
- Renal viability compromise.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT04695951
Start Date
August 1 2019
End Date
October 1 2020
Last Update
January 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica Seniors Managua
Managua, Nicaragua, 13035